// Account brief

Pfizer

Life Sciences Radar, October 2026 edition. Evidence published up to 5 October 2026; job sites read on 6 October 2026. This brief covers AI in drug discovery, and research labs and data. Every link opens the public source.

Disclosure: Andrew Wyatt, Ortent's principal, was Chief Growth Officer at Sapio Sciences, a lab software company, until April 2026. He has no current relationship with, or financial interest in, Sapio or any other supplier. Software vendors, including Sapio and its competitors, appear in this brief only where public sources name them.

Status: Ortent has reviewed this brief; it has not been independently validated. It sets out what the company and others have published. Search coverage varies by company and is described under Coverage limits, and a count of zero means none was identified, not that nothing happened. It does not predict buying intent or measure operational maturity. For this radar, process and CMC development are grouped with manufacturing and excluded from research labs and data.

Scores

Theme Priority (1 to 10) Delivery (0 to 10) Stage Commitments made public, last 12 months R&D roles open on 6 Oct 2026
AI in drug discovery 5 claimed build underway 5 4
Research labs and data 5 3 build underway 0 3

The scores rest only on what the company itself has published about each theme. Commitments and open roles are observed activity: they show what is being started or staffed now, and they never change a score.

Summary

Pfizer scores 5 out of 10 for priority on both AI in drug discovery and research labs and data: it lists scaling AI among its 2026 key priorities and says it is setting the foundation with AI-ready data. On AI in drug discovery, a build is underway to expand to more than 1,200 GPUs over two years, largely for R&D AI, and Pfizer says it uses AI across R&D, but the sources do not show an identifiable discovery system in operation, so delivery shows as claimed. On research labs and data it scores 3 out of 10 for delivery, with a build underway to make petabytes of data ready for AI. In the last 12 months five AI commitments were made public, a Chai Discovery licence, the GPU expansion, the LIGAND-AI consortium, a Pfizer Ventures investment in Enodia Therapeutics and a Boltz collaboration on foundation models, against three in the year before; no research labs and data commitment was identified in either year. On 6 October 2026 Pfizer had 4 open R&D roles tied to AI in drug discovery and 3 tied to research labs and data, one counted under both, including ML cheminformatics scientists and a high content imaging scientist.

AI in drug discovery

What the company says: Priority 5

Our 2026 key priorities are: ... Scale AI across our business.

Pfizer 2025 Form 10-K, 26 Feb 2026, p. 10

In addition, we are scaling AI across R&D, manufacturing, commercial and patient engagement to improve productivity and accelerate innovation.

Pfizer 2025 Form 10-K, 26 Feb 2026, p. 10

Build an end-to-end AI-native R&D organization

Q2 2026 earnings charts, 4 Aug 2026, p. 9

To meet the growing AI demand, over the next two years, we are expanding to more than 1,200 GPUs, largely driven by R&D application of AI.

Q4 2025 earnings call prepared remarks, 3 Feb 2026, p. 3

What it shows running: Delivery claimed, build underway

To meet the growing AI demand, over the next two years, we are expanding to more than 1,200 GPUs, largely driven by R&D application of AI.

Q4 2025 earnings call prepared remarks, 3 Feb 2026, p. 3

We are embedding AI into each functional line in R&D.

Q1 2026 earnings call prepared remarks, 5 May 2026, p. 5

It's going to be by deploying AI, which already happened in 2025 with excellent results that creates significant productivity gains. This is where we are reducing the cost of R&D.

Q4 2025 Pfizer Inc Earnings Call transcript (LSEG edited, company-hosted), 3 Feb 2026, p. 14

Commitments made public in the last 12 months: 5

  • Chai Discovery platform licence: Licence agreement that will enable Pfizer to deploy the Chai AI platform, with early access to Chai-3 and a custom model, in its drug discovery engine. New, announced, 2 Jun 2026. Published by: partner only.
  • R&D AI compute expansion (GPUs): Plans to expand to more than 1,200 GPUs over the next two years, largely driven by R&D application of AI. New, announced, 3 Feb 2026. Published by: company.
  • LIGAND-AI IHI consortium (open protein-ligand data for AI): Pfizer co-leads IHI LIGAND-AI consortium generating open protein-ligand data for AI. New, in build, 20 Jan 2026. Published by: joint release.
  • Pfizer Ventures: Enodia Therapeutics: Pfizer Ventures co-leads seed round of Enodia, whose platform uses machine-learning-enabled selectivity. New, announced, 15 Jan 2026. Published by: third party.
  • Boltz biomolecular foundation models: Boltz to refine biomolecular foundation models on Pfizer data and build custom models for discovery teams. New, announced, 8 Jan 2026. Published by: joint release.

Commitments made public in the year before: 3

Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.

R&D roles open on 6 October 2026: 4

These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.

Research labs and data

What the company says: Priority 5

We have been setting the foundation with AI-ready data, agentic workflows and compute capacity.

Q4 2025 earnings call prepared remarks, 3 Feb 2026, p. 3

Pfizer has a vast repository of small and large molecule, translational and clinical data and AI is creating the opportunity to unlock insights

Q1 2026 earnings call prepared remarks, 5 May 2026, p. 5

What it shows running: Delivery 3, build underway

Progress with making petabytes of data AI ready

Q2 2026 earnings charts, 4 Aug 2026, p. 9

Commitments made public in the last 12 months: 0

None identified in the reviewed sources.

Commitments made public in the year before: 0

None identified in the reviewed sources.

Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.

R&D roles open on 6 October 2026: 3

These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.

Two questions to investigate (Ortent's interpretation)

  1. Boltz, Chai and XtalPi are building or tuning models on Pfizer's own data and workflows, while Pfizer expands its GPU capacity and hires ML cheminformatics scientists. Who decides which outside models are adopted, and how do the R&D AI, data and analytics function and enterprise technology split those decisions?
  2. Telescope Innovations has installed a second self-driving lab at Pfizer and calls it a step towards possible full-scale use, while process development teams run their own in-house automation platform. Who decides whether self-driving labs go beyond the collaboration, and how would buying and funding that step be decided?

Coverage limits

The pfizer.com newsroom and leadership pages were blocked by a bot check, so Pfizer's own copies of partner announcements could not be checked, and SEC EDGAR refused automated access. Coverage is partial for both themes in both years, no FY2026 10-K exists yet, and the Q3 2025 earnings materials were only partly reviewed. No dedicated acquisition search was run, and the job postings are a screened set rather than a full count. The Chai licence was read through a BioSpace copy of the partner release.

// GET IN TOUCH

Clarity when it counts.

For a board, advisory or fractional engagement, or a working call on the next stage, send a note. Thirty minutes is usually enough to test fit.

Request a 30-minute intro call